Results 81 to 90 of about 22,482 (226)

Anatomic Outcomes With Faricimab vs. Aflibercept in the Head-to-Head Dosing Phase of the TENAYA/LUCERNE Trials in Neovascular AMD.

Ophthalmology (Rochester, Minn.)
PURPOSE To compare early anatomic outcomes following treatment with faricimab vs. aflibercept in a pooled analysis of the head-to-head dosing phase of the TENAYA/LUCERNE trials in neovascular age-related macular degeneration (nAMD).
Chui Ming Gemmy Cheung, Jennifer I. Lim, S. Priglinger, Giuseppe Querques, Philippe Margaron, Shriji Patel, Audrey Souverain, Jeffrey R. Willis, Ming Yang, Robyn Guymer   +9 more
semanticscholar   +1 more source

Prognostic and Predictive Role of Circulating Tumor DNA in Locally Advanced Rectal Cancer Managed With Total Neoadjuvant Therapy: A Systematic Review

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aims Circulating tumor DNA (ctDNA) has emerged as a promising biomarker of tumor burden and minimal residual disease. As total neoadjuvant therapy (TNT) increasingly supports organ‐preserving strategies in locally advanced rectal cancer (LARC), reliable markers of treatment response are needed.
Faizan Bashir, Qurat‐ul‐Aine Bhat, Jayden Allegakoen, Dorsa Shekouh, Sajida Zaiter   +4 more
wiley   +1 more source

Effect of aflibercept combined with triamcinolone acetonide on aqueous humor growth factor and inflammatory mediators in diabetic macular edema [PDF]

International Journal of Ophthalmology
AIM: To investigate the efficacy of aflibercept combined with sub-tenon injection of triamcinolone acetonide (TA) in treating diabetic macular edema (DME) and to examine changes in growth factors and inflammatory mediator levels in aqueous humor after ...
De-Shuang Li, Hong-Xia Liao, Jing-Lin Zhang, Bo Qin   +3 more
doaj   +1 more source

Aflibercept high-dose (8mg) related intraocular inflammation (IOI) – a case series

BMC Ophthalmology
Monitoring for potential inflammatory events following intravitreal anti-vascular endothelial factor (VEGF) injection is crucial with the use of new agents such as aflibercept 8 mg.
L. Hoffmann, Stephan Michels, C. Eandi, Muntadher Al Karam, Eva C. de Oliveira Figueiredo, Katja Hatz   +5 more
semanticscholar   +1 more source

Current Landscape and Future Perspectives of Diabetic Retinopathy Therapy: Pharmacological Targets, Precision Laser Technology, and Clinical Evidence

MedComm, Volume 7, Issue 7, July 2026.
Targeted biological agents targeting VEGF, integrin, dopamine D2 receptor, ROCK, and BCL‐XL have entered the clinical trial phase and deserve particular attention. The treatment paradigm has shifted toward personalized and precision medicine, positioning optimized SML as a promising adjunctive therapy.
Xinying Hu, Zhe Cha, Ao Lu, Wuping Xu, Xiaoqing Zhang, Sheng Miao, Haiwei Xu, Xuedong Xu   +7 more
wiley   +1 more source

Nonclinical study of ixo-vec gene therapy for nAMD supports efficacy for a human dose of 6E10 vg/eye and staggered dosing of fellow eyes

Molecular Therapy: Methods & Clinical Development
Ixoberogene soroparvovec (ixo-vec), formerly ADVM-022, is an adeno-associated virus (AAV) gene therapy using the AAV.7m8 capsid for intravitreal delivery (IVT) to transduce retinal tissue and produce sustained intraocular aflibercept for treating ...
Kris Poulsen, Kelly Hanna, Julio Nieves, Ngoc Nguyen, Pallavi Sharma, Ruslan Grishanin, Romu Corbau, Szilárd Kiss   +7 more
doaj   +1 more source

Intravitreal Aflibercept vs Laser Therapy for Retinopathy of Prematurity

JAMA Network Open
Key Points Question What are the long-term outcomes of preterm infants treated for severe acute-phase retinopathy of prematurity (ROP) with aflibercept injection vs laser therapy?
A. Stahl, Hidehiko Nakanishi, Domenico Lepore, Wei-Chi Wu, Noriyuki Azuma, Carlos Jacas, R. Vitti, Aditya Athanikar, Karen W. Chu, Pablo Iveli, Fei Zhao, Sergio Leal, Sarah Schlief, T. Schmelter, Thomas Miller, Evra Köfüncü, Alistair R. Fielder   +16 more
semanticscholar   +1 more source

Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion

, 2016
Remya Paulose,1 Jay Chhablani,1 Chintan J Dedhia,1 Michael W Stewart,2 Ahmad M Mansour3,4 1Smt. Kanuri Santhamma Centre for Vitreoretinal Diseases, LV Prasad Eye Institute, Hyderabad, India; 2Department of Ophthalmology, Mayo Clinic, Jacksonville, FL ...
Paulose R, Dedhia CJ, Chhablani J, Mansour AM, Stewart MW   +4 more
core  

Short-term intraocular pressure changes after intravitreal aflibercept 2 mg, aflibercept 8 mg and faricimab: a prospective, comparative study

British Journal of Ophthalmology
Background/aims Intravitreal injection (IVT) of anti-vascular endothelial growth factor agents is the standard of care for several retinal diseases but can cause intraocular pressure (IOP) elevations.
Arianna Paris, Giulio Volpe, Kathrin Perruchoud-Ader, Alex Casanova, M. Menghini, Gabriela Grimaldi   +5 more
semanticscholar   +1 more source

Aflibercept: side effects in focus [PDF]

, 2018
A new anti-angiogenic drug aflibercept has been authorized as a second-line therapy in patients with metastatic colon cancer. The use of this drug as part of FOLFIRI regimen significantly reduces the risk of disease progression (RR = 0.758, p = 0.00007).
M. Yu. Fedyanin
core   +1 more source